1. |
傅祖植.糖尿病[M]//叶任高.内科学.5版.北京:人民卫生出版社, 2000:809-810.
|
2. |
Castellarin A, Grigorian R, Bhagat N, et al. Vitrectomy with silicone oil infusion in severe diabetic retinopathy[J]. Br J Ophthalmol, 2003, 87:318-321.
|
3. |
何守志.白内障[M]//李凤鸣.中华眼科学.2版.北京:人民卫生出版社, 2006:1455-1457.
|
4. |
Ribeiro JA, Messias A, de Almeida FP, et al.The effect of intravitreal ranibizumab on intraoperative bleeding during pars plana vitrectomy for diabetic traction retinal detachment[J]. Br J Ophthalmol, 2011, 95:1337-1339.
|
5. |
Presta LG, Chen H, O'Connor SJ, et al.Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders[J].Cancer Res, 1997, 57:4593-4599.
|
6. |
Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody:crystal structure of an affinity-matured Fab in complex with antigen[J].J Mol Biol, 1999, 293:865-881.
|
7. |
Lowe J, Araujo J, Palma M, et al.RhuFab V2 inhibits VEGF-isoforms-stimulated HUVEC proliferation[J]. Invest Ophthalmol Vis Sci, 2003, 44:1828.
|
8. |
Von Hann T, Kinge B, Fossen K. Retinal artery occlusion following intravitreal anti-VEGF therapy[J]. Acta Ophthalmol, 2010, 88:263-266.
|
9. |
Fung AE, Rosenfeld PJ, Reichel E.The international intravitreal bevacizumab safety survey:using the internet to assess drug safety worldwide[J].Br J Ophthalmol, 2006, 90:1344-1349.
|
10. |
Angulo Bocco MC, Glacet-Bernard A, Zourdani A, et al. Intravitreous injection:retrospecitive study on 2028 injections and their side effects[J]. J Fr Ophtalmol, 2008, 31:693-698.
|